"Neoplasm Metastasis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
| Descriptor ID |
D009362
|
| MeSH Number(s) |
C04.697.650 C23.550.727.650
|
| Concept/Terms |
Neoplasm Metastasis- Neoplasm Metastasis
- Metastases, Neoplasm
- Neoplasm Metastases
- Metastasis
- Metastases
- Metastasis, Neoplasm
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm Metastasis".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm Metastasis".
This graph shows the total number of publications written about "Neoplasm Metastasis" by people in this website by year, and whether "Neoplasm Metastasis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 3 | 32 | 35 |
| 1995 | 5 | 28 | 33 |
| 1996 | 10 | 21 | 31 |
| 1997 | 5 | 30 | 35 |
| 1998 | 7 | 30 | 37 |
| 1999 | 2 | 25 | 27 |
| 2000 | 4 | 27 | 31 |
| 2001 | 6 | 50 | 56 |
| 2002 | 10 | 55 | 65 |
| 2003 | 14 | 76 | 90 |
| 2004 | 10 | 66 | 76 |
| 2005 | 17 | 58 | 75 |
| 2006 | 22 | 68 | 90 |
| 2007 | 13 | 72 | 85 |
| 2008 | 15 | 79 | 94 |
| 2009 | 17 | 81 | 98 |
| 2010 | 18 | 115 | 133 |
| 2011 | 16 | 123 | 139 |
| 2012 | 20 | 91 | 111 |
| 2013 | 17 | 87 | 104 |
| 2014 | 13 | 100 | 113 |
| 2015 | 14 | 106 | 120 |
| 2016 | 12 | 91 | 103 |
| 2017 | 11 | 99 | 110 |
| 2018 | 12 | 109 | 121 |
| 2019 | 11 | 93 | 104 |
| 2020 | 9 | 79 | 88 |
| 2021 | 11 | 71 | 82 |
| 2022 | 1 | 13 | 14 |
| 2023 | 0 | 4 | 4 |
| 2024 | 7 | 43 | 50 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoplasm Metastasis" by people in Profiles.
-
Palbociclib plus aromatase inhibitors in patients with metastatic breast cancer and cardiovascular diseases: real-world effectiveness. Oncologist. 2024 Dec 06; 29(12):1032-1043.
-
HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01. Nat Commun. 2024 Nov 25; 15(1):10213.
-
DNA methylation classifier to diagnose pancreatic ductal adenocarcinoma metastases from different anatomical sites. Clin Epigenetics. 2024 Nov 10; 16(1):156.
-
A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2024 Oct 15; 30(20):4609-4617.
-
Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer. JAMA Netw Open. 2024 Oct 01; 7(10):e2437871.
-
Off-Protocol Radiation Therapy in Phase 3 Metastatic Solid Tumor Trials. Int J Radiat Oncol Biol Phys. 2024 Dec 01; 120(5):1239-1244.
-
Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase?3 BEACON CRC trial. Nat Med. 2024 Nov; 30(11):3261-3271.
-
Concordance of PD-L1 Expression in Metastatic Triple-negative Breast Cancer Between the 22C3 and E1L3N Antibodies Using Combined Positive Scoring. Appl Immunohistochem Mol Morphol. 2024 Oct 01; 32(9):417-424.
-
Duration of immunotherapy in dMMR/MSI-H metastatic colorectal cancer patients. Eur J Cancer. 2024 Nov; 212:114336.
-
Vascular heterogeneity of tight junction Claudins guides organotropic metastasis. Nat Cancer. 2024 Sep; 5(9):1371-1389.